The overall objective of this project is to provide support for the performance of clinical studies of the Cancer and Leukemia Group B at the Lombardi Cancer Center at Georgetown University Medical School. The LCCCC/GUMC is an NCI-designated Comprehensive Cancer Center. Louis M. Weiner, M.D. was appointed Director of the Cancer Center on January 1, 2008. The CALGB Board of Directors approved LCCCC/GUMC as a main member institution in March, 1997. LCCCC/GUMC participates in the entire range of multimodality clinical studies including therapeutic studies, correlative science studies, and companion studies of quality of life, survivorship, and cost effectiveness analyses. LCCC faculty have been active in all three areas of CALGB activities: accrual, scientific leadership, and administrative tasks. At the present time 36 CALGB protocols are active at GUMC/LCCC. During the period from 2003-2007 622 patients have been entered onto CALGB or Intergroup trials. LCCCC/GUMC faculty are represented on 13 Committees. Three LCCCC/GUMC faculty members served as study chairs and three faculty members participated in CALGB audits. It is anticipated that LCCCC/GUMC investigators will continue their activities in the CALGB and new/young faculty members will become involved in the scientific endeavors of the group as they grow in their careers. LCCC/GUMC faculty members have been a co-author or primary author on 35 CALGB publications.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
3U10CA077597-14S2
Application #
8716921
Study Section
Subcommittee G - Education (NCI)
Program Officer
Mooney, Margaret M
Project Start
1998-04-30
Project End
2014-02-28
Budget Start
2011-04-01
Budget End
2014-02-28
Support Year
14
Fiscal Year
2013
Total Cost
$85,066
Indirect Cost
$30,361
Name
Georgetown University
Department
None
Type
Organized Research Units
DUNS #
049515844
City
Washington
State
DC
Country
United States
Zip Code
20057
Freedman, Rachel A; Seisler, D K; Foster, J C et al. (2016) Risk of acute myeloid leukemia and myelodysplastic syndrome among older women receiving anthracycline-based adjuvant chemotherapy for breast cancer on Modern Cooperative Group Trials (Alliance A151511). Breast Cancer Res Treat :
Rugo, Hope S; Barry, William T; Moreno-Aspitia, Alvaro et al. (2015) Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N0 J Clin Oncol 33:2361-9
Voorhees, Peter M; Orlowski, Robert Z; Mulkey, Flora et al. (2015) Long-term outcomes for newly-diagnosed multiple myeloma patients treated with pegylated liposomal doxorubicin and bortezomib: final results of CALGB (Alliance) 10301, a multicentre phase II study. Br J Haematol 171:373-7
Diefenbach, Catherine S; Li, Hailun; Hong, Fangxin et al. (2015) Evaluation of the International Prognostic Score (IPS-7) and a Simpler Prognostic Score (IPS-3) for advanced Hodgkin lymphoma in the modern era. Br J Haematol 171:530-8
Budd, George T; Barlow, William E; Moore, Halle C F et al. (2015) SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. J Clin Oncol 33:58-64
Yao, S; Sucheston, L E; Zhao, H et al. (2014) Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer. Pharmacogenomics J 14:241-7
Heist, Rebecca S; Wang, Xiaofei; Hodgson, Lydia et al. (2014) CALGB 30704 (Alliance): A randomized phase II study to assess the efficacy of pemetrexed or sunitinib or pemetrexed plus sunitinib in the second-line treatment of advanced non-small-cell lung cancer. J Thorac Oncol 9:214-21
Smith, Matthew R; Halabi, Susan; Ryan, Charles J et al. (2014) Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance). J Clin Oncol 32:1143-50
Du, Juan; Lopez-Verges, Sandra; Pitcher, Brandelyn N et al. (2014) CALGB 150905 (Alliance): rituximab broadens the antilymphoma response by activating unlicensed NK cells. Cancer Immunol Res 2:878-89
Burstein, Harold J; Cirrincione, Constance T; Barry, William T et al. (2014) Endocrine therapy with or without inhibition of epidermal growth factor receptor and human epidermal growth factor receptor 2: a randomized, double-blind, placebo-controlled phase III trial of fulvestrant with or without lapatinib for postmenopausal women J Clin Oncol 32:3959-66

Showing the most recent 10 out of 69 publications